Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
111 hedge funds and large institutions have $607M invested in Acceleron Pharma in 2015 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 46 increasing their positions, 31 reducing their positions, and 15 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 31
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5% less funds holding
Funds holding: 117 → 111 (-6)
23% less capital invested
Capital invested by funds: $785M → $607M (-$178M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
67% less call options, than puts
Call options by funds: $1.8M | Put options by funds: $5.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.2M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$5.04M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$4.51M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.67M |
| 5 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCI
Polaris Venture Management Co IV
Boston,
Massachusetts
|
-$12.2M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$10.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.69M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$3.46M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.56M |
XLRN Hedge Fund Activity: Q3 2015 in Review
111 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2015, worth a combined $607M — down 23% from $785M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of XLRN and 9 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 46 added.
The largest buyer was Vanguard Group, adding an estimated $11.2M. The largest seller was Polaris Venture Management Co IV, cutting an estimated $12.2M.
- 111 institutional investors held Acceleron Pharma (XLRN) as of Q3 2015, down from 117 in Q2 2015.
- Funds reported $607M of Acceleron Pharma stock for Q3 2015, down 23% quarter-over-quarter.
- 9 funds opened new Acceleron Pharma positions in Q3 2015 and 15 closed out, a net change of -6 holders.
- The largest Acceleron Pharma buyer in Q3 2015 was Vanguard Group, an estimated $11.2M added.
- The largest Acceleron Pharma seller in Q3 2015 was Polaris Venture Management Co IV, an estimated $12.2M sold.
Based on aggregated 13F filings for Q3 2015.